PDSB News and Press, PDS Biotechnology Corporation From 06/15/21

FLORHAM PARK, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune &#x...

Document Security Systems DSS -41% after secures $43.5M capital via equity raise.PDS Biotechnology PDSB -16% on proposing stock offering.Sage Therapeutics SAGE -12% after disappointing zuranolone secondary data in depression study.Vascular Biogenics VBLT -12...

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune &#x...

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced it...

Over the next two Fridays, The FTSE Russell will post updates to its equity index reconstitutions that were announced last Friday. These updates and adjustments to the original lists provided could occur for a number of reasons. The reactions to stock prices impacted could be strong as these a...

PDS Biotech presented the first analysis from the Phase 2 trial testing PDS0101 in HPV16+ (human papilloma virus 16 positive) cancers. The data presentation was from the first 25 patients out of the target enrollment of 56 patients. The trial enrolls patients who have failed first-line treatme...

PDS Biotech presented the first analysis from the Phase 2 trial testing PDS0101 in HPV16+ (human papilloma virus 16 positive) cancers. The data presentation was from the first 25 patients out of the target enrollment of 56 patients. The trial enrolls patients who have failed first-line treatme...

Photo by luismmolina/E+ via Getty Images After losing more than a quarter of value yesterday, the shares of PDS Biotechnology ([[PDSB]] +17.6%) have rebounded today in reaction to encouraging Phase 2 data presented at the 2021 ASCO Annual Meeting for PDS0101 in human papillomavirus ((HPV...

Gainers: Clover Health Investments CLOV +70%, Precipio PRPO +15%, GBS (GBS) +15%, PDS Biotechnology PDSB +15%, Cyclerion Therapeutics CYCN +10%.Losers: Ra Medical Systems RMED -19%, HOOKIPA Pharma HOOK -15%, AC Immune (ACIU...

Clover Health Investments (CLOV) +37%.Aytu Biopharma (AYTU) +20%.NextDecade Corporation NEXT +20% after Morgan Stanley upgrades on Rio Grande LNG outlook.Cyclerion Therapeutics (CYCN) +16%.The Wendy's (WEN) +16%.Stitch Fix SFIX +14% on Q3 results.PDS Biotechnology PDS...